Niehaus, Ines Marina ORCID: 0000-0002-4214-6898 and Dintsios, Charalabos-Markos ORCID: 0000-0003-3469-092X (2018). Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs. Health Policy, 122 (6). S. 599 - 607. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-6054
Full text not available from this repository.Abstract
The early benefit assessment of pharmaceuticals in Germany and their preceding market authorization pursue different objectives. This is reflected by the inclusion of varying confirmatory endpoints within the evaluation of oncology drugs in early benefit assessment versus market authorization, with both relying on the same evidence. Data from assessments up to July 2015 are used to estimate the impact of explorative in comparison to confirmatory endpoints on market authorization and early benefit assessment by contrasting the benefit-risk ratio of EMA and the benefit-harm balance of the HTA jurisdiction. Agreement between market authorization and early benefit assessment is examined by Cohen's kappa (k). 21 of 41 assessments were considered in the analysis. Market authorization is more confirmatory than early benefit assessment because it includes a higher proportion of primary endpoints. The latter implies a primary endpoint to be relevant for the benefit-harm balance in only 67% of cases (0.078). Explorative mortality endpoints reached the highest agreement regarding the mutual consideration for the risk-benefit ratio and the benefit-harm balance (0.000). For explorative morbidity endpoints (-0.600), quality of life (-0.600) and side effects (-0.949) no agreement is ascertainable. To warrant a broader confirmatory basis for decisions supported by HTA, closer inter-institutional cooperation of approval authorities and HTA jurisdictions by means of reliable joint advice for manufacturers regarding endpoint definition would be favorable. (C) 2018 Elsevier B.V. All rights reserved.
Item Type: | Journal Article | ||||||||||||
Creators: |
|
||||||||||||
URN: | urn:nbn:de:hbz:38-184189 | ||||||||||||
DOI: | 10.1016/j.healthpol.2018.03.017 | ||||||||||||
Journal or Publication Title: | Health Policy | ||||||||||||
Volume: | 122 | ||||||||||||
Number: | 6 | ||||||||||||
Page Range: | S. 599 - 607 | ||||||||||||
Date: | 2018 | ||||||||||||
Publisher: | ELSEVIER IRELAND LTD | ||||||||||||
Place of Publication: | CLARE | ||||||||||||
ISSN: | 1872-6054 | ||||||||||||
Language: | English | ||||||||||||
Faculty: | Faculty of Medicine | ||||||||||||
Divisions: | Faculty of Medicine > Sonstiges > Zentrum für Versorgungsforschung Köln | ||||||||||||
Subjects: | Medical sciences Medicine | ||||||||||||
Uncontrolled Keywords: |
|
||||||||||||
Refereed: | Yes | ||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/18418 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |